Td Asset Management Inc Genmab A/S Transaction History

Td Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$35.87 - $47.12 $759,403 - $997,577	-21,171 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$41.55 - $48.72 $879,655 - $1.03 Million	21,171 New	21,171 $925,000
Q2 2020 Aug 13, 2020	SELL	$20.05 - $33.89 $371,406 - $627,778	-18,524 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.15 - $25.22 $20,957 - $30,818	1,222 Added 7.06%	18,524 $304,000
Q4 2019 Feb 11, 2020	SELL	$18.88 - $24.14 $2,341 - $2,993	-124 Reduced 0.71%	17,302 $284,000
Q3 2019 Nov 07, 2019	BUY	$18.0 - $21.38 $313,668 - $372,567	17,426 New	17,426 $286,000

238

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.